trending Market Intelligence /marketintelligence/en/news-insights/trending/iehuQxOiWFI9ibpz3sdqgw2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Terumo stops development of injectable surgical anesthetic in Japan

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Terumo stops development of injectable surgical anesthetic in Japan

Terumo Corp. will no longer develop the injectable surgical anesthetic TPM/Propofol for the Japanese market.

The Japanese healthcare equipment company ended its collaboration with Australia's Avecho Biotechnology Ltd. to develop a reformulation of the TPM/Propofol product.

Propofol is a general anesthetic used to induce and maintain sedation during surgery.

The vehicle used for the TPM/Propofol formulation was shown to be unsafe for a complete 24-hour infusion in previous toxicology studies, Avecho said. Due to this, the indication for the product would be restricted to the induction and short-term maintenance of anesthesia.

In a statement to Avecho, Terumo said it decided not to support further development of TPM/Propofol as safety concerns related to the length of infusion would be difficult to address with Japanese regulators.

"Given the size of the Japanese market, Terumo was unwilling to consider launching a propofol product with a restricted indication," Avecho said in a news release. Avecho added that it has yet to decide if it will continue to develop the existing TPM/Propofol formulation only for acute use or further optimize the formulation to resume the toxicology studies.